In clinical trials, cholelithiasis was reported by 1.6% of those taking semaglutide and 0.7% of those taking placebo. In terms of cholecystitis, the rates were 0.6% with the higher dose of semaglutide vs 0.2% with placebo. Impotence, mucositis, and hyperhidrosis have not been cited as significant concerns associated with semaglutide use.
Learn more about adverse effects associated with semaglutide.
This Fast Five Quiz was excerpted and adapted from the Medscape articles semaglutide, More STEP Data: Semaglutide Cuts Weight, Cravings, Beats Liraglutide, All About Wegovy for Weight Loss, and Type 2 Diabetes Mellitus Treatment & Management.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Lead image: Dreamstime
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Semaglutide - Medscape - Jan 20, 2022.